Document Title: Beta Drugs Limited Joint Venture Announcement for Algeria Oncology Operations
Summary of Key Information:
Reporting Period (Quarter/Year): Not Specified
Nature of Filing / Announcement: Outcome of Board Meeting - Joint Venture Agreement
Date of Board Meeting / Approval: November 19, 2026
Audit Opinion: Not Specified
Auditor's Comment: Not Specified
Key Financial Highlights:
Standalone Results: Not Specified
Consolidated Results: Not Specified
Segment-wise Performance: Not Specified
Corporate Actions:
- Approved entry into joint venture agreement with IMGSA Groupe SPA of Algeria
- Joint venture company to be named IMGSA Oncologie SPA (to be incorporated in Algeria)
- Joint venture purpose: manufacturing and marketing of oncology pharmaceutical products in Algeria
- Ownership structure: Beta Drugs Limited - 49%, IMGSA Groupe SPA - 51%
- Total investment in JV: USD 8.7 Million
- Beta's investment: USD 3 million cash over 3 years plus technology transfer valued at USD 1.26 million
- IMGSA's contribution: USD 4.43 million in form of plant and machinery transfer
- JV will take over existing Oncology Plant currently owned by IMGSA
Regulatory Disclosures:
- Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026 referenced
- Transaction does not qualify as related party transaction pre-incorporation
- JV will become related party post-incorporation
- Governmental approvals required: Incorporation according to laws of People's Democratic Republic of Algeria
Other Significant Information:
- IMGSA Groupe SPA background: Algerian conglomerate founded in 2003 with presence in healthcare, real estate, agriculture
- IMGSA turnover: US$ 100 Million for year ended December 2025 with 30% from exports
- IMGSA export markets: Tunisia, Morocco, Yemen, Mauritania, Italy, Spain
- Existing relationship: Beta has supplied semi-finished/finished formulations to IMGSA for 4 years
- Beta supported IMGSA in oncology product registrations for Algeria market
- Plant details: Equipped with production lines for Injectables and Oral Solid dosage forms, has been supplying to Algeria national tenders
- Governance structure: Beta entitled to appoint 3 board members, IMGSA entitled to appoint 2 board members
- Operational control: Beta to appoint CEO/General Manager and oversee day-to-day operations
- Beta has affirmative voting rights over key governance matters including capital structure changes, capital expenditure, dissolution
- Transaction subject to customary closing formalities
- Board meeting duration: 9:00 a.m. to 10:50 a.m.